These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35481358)

  • 1. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells.
    Sadeghi Najafabadi SA; Bolhassani A; Aghasadeghi MR
    Immunotherapy; 2022 Jun; 14(8):639-654. PubMed ID: 35481358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
    Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
    Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell.
    Diao L; Liu M
    Adv Sci (Weinh); 2023 Aug; 10(22):e2300121. PubMed ID: 37254712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor inhibition in vivo.
    Zhu H; Wang K; Wang Z; Wang D; Yin X; Liu Y; Yu F; Zhao W
    Acta Biomater; 2022 Jan; 138():491-504. PubMed ID: 34757230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice.
    Yildirim M; Yildirim TC; Turay N; Bildik T; Ibibik B; Evcili I; Ersan PG; Tokat UM; Sahin O; Gursel I
    Immunol Lett; 2021 Nov; 239():32-41. PubMed ID: 34418488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy.
    Naseri M; Bozorgmehr M; Zöller M; Ranaei Pirmardan E; Madjd Z
    Oncoimmunology; 2020 Jun; 9(1):1779991. PubMed ID: 32934883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses.
    Zuo B; Zhang Y; Zhao K; Wu L; Qi H; Yang R; Gao X; Geng M; Wu Y; Jing R; Zhou Q; Seow Y; Yin H
    J Hematol Oncol; 2022 Apr; 15(1):46. PubMed ID: 35488312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer vaccines as promising immuno-therapeutics: platforms and current progress.
    Liu J; Fu M; Wang M; Wan D; Wei Y; Wei X
    J Hematol Oncol; 2022 Mar; 15(1):28. PubMed ID: 35303904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
    Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
    Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy.
    Zhang Y; Zuo B; Yu Z; Zhao K; Zhang Y; He K; Seow Y; Yin H
    Mol Ther; 2023 Dec; 31(12):3579-3593. PubMed ID: 37919900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine.
    Xia J; Miao Y; Wang X; Huang X; Dai J
    Biomed Pharmacother; 2022 Aug; 152():113250. PubMed ID: 35700679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
    Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
    J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies.
    Li J; Li J; Peng Y; Du Y; Yang Z; Qi X
    J Control Release; 2023 Jan; 353():423-433. PubMed ID: 36470333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Cancer Vaccine Research.
    Liu N; Xiao X; Zhang Z; Mao C; Wan M; Shen J
    ACS Biomater Sci Eng; 2023 Nov; 9(11):5999-6023. PubMed ID: 37921277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.